Sequana Medical receives CE-mark approval for the use of its alfapump® system in cancer patients with malignant ascites
Innovative implantable pump system set to benefit patients with ascites caused by cancer..
Sequana Medical has been nominated as a finalist in the 'maturity stage' category of the Swiss Technology Award 2012.
University Hospital Zurich and University Inselspital Berne implant their first patients with Sequana Medical’s alfapump® System
Swiss company’s innovative technology for the management of refractory ascites significantly reduces the need for large-volume paracentesis, improving patient quality of life...
Sequana Medical’s alfapump® system proves to be a safe and efficacious breakthrough technology in ascites management
Data presented at the International Liver Disease Meeting demonstrated that the alfapump system significantly decreases the need for Large Volume Paracentesis and can reduce hospital visit...
Sequana Medical’s alfapump® system receives reimbursement in Germany for breakthrough technology in ascites management
NUB grants approval for fifteen leading hepatology centres in Germany.
Sequana Medical from Zürich, Switzerland has been nominated for one of the European medical-device industry’s most prestigious awards...
NHS National Innovation Centre estimates Sequana Medical’s alfapump® system could save the NHS £50 million in ascites care annually
NHS National Innovation Centre supports the cost effectiveness of Sequana Medical’s ALFApump System.
The Medical University of Vienna and Vienna General Hospital perform the first two commercial implants worldwide of Sequana Medical’s alfapump system.
New technology expands treatment options for patient with refractory ascites due to liver cirrhosis.
NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG (www.sequanamedical.com) as it prepares for the upcoming launch of the alfapump system in Europe.